Press Releases
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April
- Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients’ needs
Incheon, S. Korea, Jan 15, 2025 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.
During the main track presentation, Samsung Biologics’ CEO and President John Rim said, “Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the opening of Bio Campus II and launch of antibody-drug conjugate (ADC) services.” He added, “We’ll continue to invest in new modalities and technologies to better address client needs, maximizing satisfaction and ensuring the delivery of highest-quality products.”
Key business updates include:
ADC services: To address the increasing demand for ADC-based therapeutics, Samsung Biologics has commenced ADC services at its new dedicated facility. Building on the company’s expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics’ service scope spans late stage discovery, development, and conjugation. Samsung Biologics recently expanded its collaboration with LigaChem Biosciences to support a series of their ADC programs at Samsung Biologics’ new dedicated ADC facility.
Opening of Japan office: To better support Samsung Biologics’ expanding global client base, the company announced plans to open a regional office in Tokyo this year. The local presence will boost Samsung Biologics ability to support and grow its increasing partnerships in Japan.
Expanded Drug Product (DP) services: As part of continued efforts to expand service offerings, Samsung Biologics is investing in pre-filled syringe (PFS) capabilities. The company’s fully automated PFS DP line will be CGMP ready by 2027.
Enhanced development capabilities: Samsung Biologics plans to better support global pharma and emerging biotech companies by investing in core development capabilities. The company is offering services incorporating new tech platforms, including S-HiConTM, S-TensifyTM, S-AfuCHOTM, and S-OptiChargeTM, that ensure higher productivity and quality of a molecule for successful and accelerated drug development.
Capacity expansion: Samsung Biologics will mark a new phase of growth with the opening of Bio Campus II this year. Plant 5, the first facility of the new site, will be operational in April this year and bring up the total capacity to 784,000 liters. The company is also considering the construction of a sixth plant to proactively respond to the increasing demand for biologics which will increase its total production capacity to 964,000 liters, upon board approval.
Digital transformation: As part of efforts to maximize operational efficiency and client satisfaction, Samsung Biologics will continue to invest in further building its integrated digital systems spanning quality, manufacturing, and operations. Incorporating artificial intelligence and digital twin technology, the company plans to provide clients with data-enabled solutions and insight to optimize project timelines without compromising quality.
- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April
- Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients’ needs
Incheon, S. Korea, Jan 15, 2025 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.
During the main track presentation, Samsung Biologics’ CEO and President John Rim said, “Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the opening of Bio Campus II and launch of antibody-drug conjugate (ADC) services.” He added, “We’ll continue to invest in new modalities and technologies to better address client needs, maximizing satisfaction and ensuring the delivery of highest-quality products.”
Key business updates include:
ADC services: To address the increasing demand for ADC-based therapeutics, Samsung Biologics has commenced ADC services at its new dedicated facility. Building on the company’s expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics’ service scope spans late stage discovery, development, and conjugation. Samsung Biologics recently expanded its collaboration with LigaChem Biosciences to support a series of their ADC programs at Samsung Biologics’ new dedicated ADC facility.
Opening of Japan office: To better support Samsung Biologics’ expanding global client base, the company announced plans to open a regional office in Tokyo this year. The local presence will boost Samsung Biologics ability to support and grow its increasing partnerships in Japan.
Expanded Drug Product (DP) services: As part of continued efforts to expand service offerings, Samsung Biologics is investing in pre-filled syringe (PFS) capabilities. The company’s fully automated PFS DP line will be CGMP ready by 2027.
Enhanced development capabilities: Samsung Biologics plans to better support global pharma and emerging biotech companies by investing in core development capabilities. The company is offering services incorporating new tech platforms, including S-HiConTM, S-TensifyTM, S-AfuCHOTM, and S-OptiChargeTM, that ensure higher productivity and quality of a molecule for successful and accelerated drug development.
Capacity expansion: Samsung Biologics will mark a new phase of growth with the opening of Bio Campus II this year. Plant 5, the first facility of the new site, will be operational in April this year and bring up the total capacity to 784,000 liters. The company is also considering the construction of a sixth plant to proactively respond to the increasing demand for biologics which will increase its total production capacity to 964,000 liters, upon board approval.
Digital transformation: As part of efforts to maximize operational efficiency and client satisfaction, Samsung Biologics will continue to invest in further building its integrated digital systems spanning quality, manufacturing, and operations. Incorporating artificial intelligence and digital twin technology, the company plans to provide clients with data-enabled solutions and insight to optimize project timelines without compromising quality.